Ocular Therapeutix insider plans sale of 124,882 shares

Ocular Therapeutix insider Pravin Dugel filed to sell up to 124,882 shares of common stock.

Accepted by SEC EDGAR 02/12/2026 - 04:20 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Ocular Therapeutix insider Pravin Dugel filed to sell up to 124,882 shares of common stock. The shares were acquired on 02/11/2026 through restricted stock vesting under a registered plan and are expected to be sold around 02/12/2026 on the NASDAQ through Morgan Stanley Smith Barney LLC.

The filing notes that 217,691,779 shares of Ocular Therapeutix common stock are outstanding. It also discloses a prior sale by Dugel of 19,530 shares of common stock on 11/24/2025 for gross proceeds of 235,082.61.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the OCUL Form 144 filing by Pravin Dugel disclose?

The filing discloses Pravin Dugel’s intent to sell up to 124,882 OCUL common shares. These shares came from restricted stock that vested on 02/11/2026 under a registered plan and are planned for sale on NASDAQ through Morgan Stanley Smith Barney LLC.

How many Ocular Therapeutix (OCUL) shares are planned to be sold?

The notice covers a proposed sale of 124,882 OCUL common shares. These shares were recently acquired via restricted stock vesting and are listed for sale through Morgan Stanley Smith Barney LLC Executive Financial Services on the NASDAQ exchange with an approximate sale date of 02/12/2026.

How were the OCUL shares in this Form 144 acquired?

The 124,882 OCUL common shares were acquired on 02/11/2026 through restricted stock vesting under a registered plan. The issuer granted these shares, and the filing lists the acquisition as “Not Applicable” for payment nature, indicating no separate cash purchase at vesting.

What prior OCUL share sales by Pravin Dugel are disclosed?

The filing reports a prior sale by Pravin Dugel of 19,530 OCUL common shares on 11/24/2025, generating gross proceeds of 235,082.61. This disclosure covers securities sold during the past three months for aggregation under Rule 144 requirements.

How many Ocular Therapeutix (OCUL) shares are outstanding in this filing?

The document states that 217,691,779 OCUL common shares are outstanding. This figure provides context for the planned sale of 124,882 shares, helping investors gauge the relative size of the proposed transaction versus the total share count.

Which broker and exchange are used for the planned OCUL share sale?

The planned sale of 124,882 OCUL shares will be handled by Morgan Stanley Smith Barney LLC Executive Financial Services. The shares are expected to be sold on the NASDAQ exchange, with an approximate sale date listed as 02/12/2026 in the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001700917
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	OCULAR THERAPEUTIX, INC.
SEC File Number	001-36554
Address of Issuer	15 Crosby Drive Bedford MASSACHUSETTS 01730
Phone	781-357-4000
Name of Person for Whose Account the Securities are To Be Sold	PRAVIN DUGEL
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	124882	1128583.61	217691779	02/12/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/11/2026	Restricted stock vesting under a registered plan	Issuer			124882	02/11/2026	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
PRAVIN DUGEL 15 Crosby Drive Bedford MA 01730	Common	11/24/2025	19530	235082.61

144: Remarks and Signature

Remarks
Date of Notice	02/12/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Pravin Dugel
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)